TNF-alpha Inhibitor Treatment in an Ankylosing Spondylitis Patient with Secondary Amyloidosis that Manifest with Diarrhea: A Case Report.
10.3904/kjm.2015.89.2.259
- Author:
Jae Hyun LEE
1
;
Jinyoung MOON
;
Hyun Woo LEE
;
Sung Hae CHANG
;
Eun Bong LEE
;
Yeong Wook SONG
;
Eun Young LEE
Author Information
1. Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. elee@snu.ac.kr
- Publication Type:Case Report
- Keywords:
Amyloidosis;
Spondylitis, Ankylosing;
TNFR-Fc fusion protein
- MeSH:
Adipose Tissue;
Amyloid;
Amyloidosis*;
Arthritis, Rheumatoid;
Crohn Disease;
Diarrhea*;
Humans;
Korea;
Plaque, Amyloid;
Spondylitis, Ankylosing*;
Tumor Necrosis Factor-alpha*;
Etanercept
- From:Korean Journal of Medicine
2015;89(2):259-263
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Secondary amyloidosis (Amyloid A amyloidosis) occurs when serum amyloid S accumulates in various tissues and organs. It often accompanies chronic inflammatory disease, especially rheumatoid arthritis, as well as ankylosing spondylitis (AS) and Crohn's disease. Although amyloid deposits were reported in 7% of the abdominal fatty tissue samples from AS patients, most of the patients had no symptoms. In a large study, 1.1% of 730 patients with AS were diagnosed with amyloidosis. Most of them showed renal involvement, while none had gastrointestinal symptoms. In South Korea, only a few cases of gastrointestinal involvement of secondary amyloidosis have been reported in AS patients, and there is no report on the effect of a tumor necrosis factor (TNF)-alpha inhibitor. We report a case of secondary amyloidosis in an AS patient who improved with the TNF-alpha inhibitor etanercept.
